Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Resmed Inc’s stock clocked out at $270.07, down -1.08% from its previous closing price of $273.01. In other words, the price has decreased by -$1.08 from its previous closing price. On the day, 0.97 million shares were traded. RMD stock price reached its highest trading level at $272.18 during the session, while it also had its lowest trading level at $267.0.
Ratios:
To gain a deeper understanding of RMD’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 32.24 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 23.72. For the most recent quarter (mrq), Quick Ratio is recorded 2.53 and its Current Ratio is at 3.44. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, Citigroup on September 18, 2025, initiated with a Buy rating and assigned the stock a target price of $330.
RBC Capital Mkts Upgraded its Sector Perform to Outperform on July 15, 2025, while the target price for the stock was maintained at $294.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 07 ’25 when Farrell Michael J. sold 8,009 shares for $282.85 per share. The transaction valued at 2,265,332 led to the insider holds 467,792 shares of the business.
Farrell Michael J. bought 8,009 shares of RMD for $2,265,332 on Oct 07 ’25. On Oct 07 ’25, another insider, Ghoshal Kaushik, who serves as the Former Officer of the company, bought 4,876 shares for $283.42 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RMD now has a Market Capitalization of 39414214656 and an Enterprise Value of 39184617472. As of this moment, Resmed’s Price-to-Earnings (P/E) ratio for their current fiscal year is 28.40, and their Forward P/E ratio for the next fiscal year is 22.43. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.57. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.66 while its Price-to-Book (P/B) ratio in mrq is 6.62. Its current Enterprise Value per Revenue stands at 7.614 whereas that against EBITDA is 21.063.
Stock Price History:
The Beta on a monthly basis for RMD is 0.88, which has changed by 0.13312912 over the last 52 weeks, in comparison to a change of 0.13724327 over the same period for the S&P500. Over the past 52 weeks, RMD has reached a high of $293.81, while it has fallen to a 52-week low of $199.92. The 50-Day Moving Average of the stock is -2.86%, while the 200-Day Moving Average is calculated to be 8.09%.
Shares Statistics:
It appears that RMD traded 1.00M shares on average per day over the past three months and 850520 shares per day over the past ten days. A total of 146.39M shares are outstanding, with a floating share count of 145.03M. Insiders hold about 0.63% of the company’s shares, while institutions hold 65.49% stake in the company. Shares short for RMD as of 1759190400 were 8806208 with a Short Ratio of 8.80, compared to 1756425600 on 8510839. Therefore, it implies a Short% of Shares Outstanding of 8806208 and a Short% of Float of 6.950000000000001.
Dividends & Splits
With its trailing 12-month dividend rate of 2.12, RMD has a forward annual dividend rate of 2.19. Against a Trailing Annual Dividend Yield of 0.0077652824. The stock’s 5-year Average Dividend Yield is 0.82. . The current Payout Ratio is 22.30% for RMD, which recently paid a dividend on 2025-08-14 with an ex-dividend date of 2025-08-14. Stock splits for the company last occurred on 2010-08-31 when the company split stock in a 2:1 ratio.
Earnings Estimates
The stock of Resmed Inc (RMD) is currently drawing attention from 13.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is $2.7, with high estimates of $2.79 and low estimates of $2.6.
Analysts are recommending an EPS of between $12.0 and $10.32 for the fiscal current year, implying an average EPS of $10.86. EPS for the following year is $11.95, with 19.0 analysts recommending between $12.67 and $11.5.
Revenue Estimates
In . The current quarter, 18 analysts expect revenue to total $1.33B. It ranges from a high estimate of $1.36B to a low estimate of $1.3B. As of . The current estimate, Resmed Inc’s year-ago sales were $1.22BFor the next quarter, 18 analysts are estimating revenue of $1.4B. There is a high estimate of $1.43B for the next quarter, whereas the lowest estimate is $1.37B.
A total of 26 analysts have provided revenue estimates for RMD’s current fiscal year. The highest revenue estimate was $5.7B, while the lowest revenue estimate was $5.5B, resulting in an average revenue estimate of $5.6B. In the same quarter a year ago, actual revenue was $5.15BBased on 26 analysts’ estimates, the company’s revenue will be $6.02B in the next fiscal year. The high estimate is $6.2B and the low estimate is $5.87B.
